Off-label use of semaglutide and tirzepatide shows promise in type 1 diabetes

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c) levels and body weight among adults with type 1 diabetes (T1D). These findings suggest a potential new therapeutic approach for improving glycemic control and addressing obesity in T1D, an area with few pharmacologic advancements beyond insulin therapy.